Debut of Life Science Industry’s First Benchtop Proteomic and Epigenetic Sample Preparation System

MAGic™ Sample Processor Eliminates Manual Methodologies, Increases Productivity

CARLSBAD, Calif.–Life Technologies Corporation (NASDAQ:LIFE) today debuted the life science industry’s first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols. The Invitrogen MAGic™ Sample Processor enables researchers to cut protocol time in half, dramatically reduce experimental errors, and perform technically challenging experiments in protein purification and epigenetics.

“The MAGic Sample Processor is designed to address reproducibility challenges in research”

Protein purification is a series of processes to isolate a single type of protein from a complex mixture, which is typically a biological tissue or microbial culture. The purification process is critical for characterizing function, structure and interactions of proteins. Research scientists also utilize protein purification in epigenetics to understand how proteins regulate DNA and RNA transcription. While initial applications of the MAGic Sample Processor are in protein isolation and epigenetics, including the isolation of recombinant proteins and immunoprecipitation of large DNA-protein complexes, the system is uniquely flexible to meet a variety of genomic and proteomic applications.

The MAGic Sample Processor houses innovative microfluidics, thermal controls and integrated magnetic separation technology, which allows researchers to easily automate their protein purification and epigenetics methods without relying on centralized facilities. The benchtop system is capable of simultaneously handling 12 samples using a proprietary cartridge to reduce variability commonly attributed with traditional manual approaches, and easily runs standard or customized protocols. Additionally, the system is combined with new reagents based on the company’s leading proprietary Dynabeads® magnetic separation technology.

“The MAGic Sample Processor is designed to address reproducibility challenges in research,” said Nicolas Barthelemy, President of the Life Technologies Cell Systems Division. “Scientists are under pressure to be more productive and MAGic, along with our other benchtop devices such as the iBlot™ Dry Blotting Device and the BenchPro™ 4100 Western Processing Device, is enabling researchers to spend less time doing repetitive work and more time where it matters – analyzing their results.”

The MAGic Sample Processor is now commercially available.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: https://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.